Quant Biomarkers AG, a Swiss life sciences technology company, specializes in predictive biomarker-based platforms for early detection of chronic disease risk and new therapeutic targets. Leveraging innovations in AI/ML & novel biomarkers, we address healthcare challenges in aging populations.
Products, services, technology
Our initial focus is on chronic kidney disease & nephroprotective therapy. Lead products include RenoPredict®, an AI/ML based CDSS, CKD prognostic based on SoC biomarkers and RenoRisk® panel of novel biomarkers measured in urine for glomerulonephritis & CKD early risk detection and stratification.
Cooperation possibilities
Biomarker platforms, CDx and Dx discovery, development, optimisation, technology switches and validation, from pre-clinical to market robust biomarkers. Hospital care focused on Chronic Kidney Disease (CKD) and CardioRenal Metabolic Syndrome (CRS).
Some insights
Quant Biomarkers AG. contributes to making the world a better place through its focus on advancing healthcare with innovative solutions. With a specific emphasis on Kidney Health and early detection of CKD, we strive to improve health outcomes & enhance the quality of life for individuals worldwide.
We are proud of our commitment to early chronic diaseses detection. Innovative solutions for therapeutic advancement, leveraging cutting-edge technologies, mpact on aging populations & contributing to global health, effective clinical decisions, improving and extending lives & cut healthcare costs.
Everyone that inspire us to push boundaries, embrace innovation, and contribute meaningfully to the advancement of biotechnology for the benefit of society.
Platform technologies, Biomarkers, R&D, Dignostics, Partnering and collaborations,
Helping people to stay healthy and happy.
Helping create a supportive environment to connect with key stakeholders.
Hospital platforms, AI/ML partners, pharmaceutical companies, insurers, and diagnostic labs.